久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

英國Enigma Diagnostics  
Enigma DiagnosticsLimited是一家總部位于英國的未上市公司，致力于為分散和即時設(shè)置開發(fā)新一代快速分子診斷儀器平臺。

　　Enigma的創(chuàng)新型專有技術(shù)將實時聚合酶鏈反應(yīng)的速度和靈敏度與現(xiàn)場分散與即時測試所需的簡易性相結(jié)合，可以在45分鐘之內(nèi)提供原始樣本的測試結(jié)果。

　　該公司正瞄準(zhǔn)眾多價值數(shù)十億英磅的市場，重點則放在臨床和高值應(yīng)用市場。Enigma的商業(yè)戰(zhàn)略是最大化其市場領(lǐng)先的快速診斷即時與現(xiàn)場設(shè)備與化驗平臺的持續(xù)運轉(zhuǎn)帶來的營收，這些設(shè)備和平臺來源于該公司廣泛的已發(fā)布和提交專利申請的知識產(chǎn)權(quán)組合。Enigma將與一些市場領(lǐng)導(dǎo)者合作，這些市場領(lǐng)導(dǎo)者需要有全球的市場滲透力，并且要適當(dāng)建立內(nèi)部銷售和營銷能力以指導(dǎo)其產(chǎn)品的分銷過程。

　　Enigma 擁有 Defence Science TechnologyLaboratory授予的一系列專利（這些專利體現(xiàn)了英國國防部 (UK Ministry ofDefence)逾15年來對研究的大力支持）的獨家許可以及美國應(yīng)用生物系統(tǒng)公司 (Applied Biosystems) 和CeleraLicences的實時聚合酶鏈反應(yīng)設(shè)備推廣的許可。Enigma的研發(fā)活動已經(jīng)產(chǎn)生了50多個致力于實時聚合酶鏈反應(yīng)和更廣泛分子技術(shù)的全球?qū)＠盗小＿@些專利中有許多已經(jīng)得到美國、歐盟和日本等核心商業(yè)地區(qū)的承認(rèn)，并且在眾多其它關(guān)鍵地區(qū)也有范圍更廣的申請和授權(quán)。

Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings. Enigma’s innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma’s commercialisation strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of- care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.